Looking for new ideas as you put money to work in the stock market? Jim Cramer has plenty of them!» Read More
*VIX jumps on Russia, Ukraine concerns. NEW YORK, Aug 15- U.S. stocks ended mixed on Friday, paring an earlier selloff sparked by reports of Ukraine shelling a Russian armored column.
U.S. stocks ended the week mixed after news of fresh conflict between Russia and Ukraine.
Take a look at some of Friday's midday movers:
A spokeswoman for Roche declined to comment on the report. There has long been speculation that Roche might swallow Chugai- following a similar buyout of U.S. biotech group Genentech in 2009- to maximise exposure to the Japanese drugs market, the world's second largest after the United States.
Aug 15- Gilead Sciences Inc said an arbitration panel rejected Roche Holding AG's patent infringement claims related to Gilead's hepatitis C drug, Sovaldi.
Aug 15- Roche Holding AG is in talks to buy the almost 40 percent stake in Japan's Chugai Pharmaceutical Co Ltd that it does not already own for about $10 billion, Bloomberg reported, citing people familiar with the matter.
Aug 15- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. Achievement of 100 percent cure rate confirms the competitive profile of NS5A, Wells Fargo Securities analyst Brian Abrahams wrote in a note.
Aug 15- Gilead Sciences Inc said an arbitration panel has ruled in its favor, rejecting patent infringement claims from Roche Holding AG, related to Gilead's hepatitis C drug, Sovaldi.
NEW YORK, Aug 13- Biotechnology company InterMune Inc is working with financial advisers to evaluate strategic options as it braces for potential takeover interest from larger drugmakers, people familiar with the matter said.
Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.
Aug 1- Biota Pharmaceuticals Inc said its influenza treatment failed to meet the main goal in a mid-stage study, about two months after the company lost a key government contract supporting the drug's development.
LONDON, July 31- AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types. AstraZeneca said it would present further data looking at MEDI4736 in lung cancer, as well as early results for head and neck cancer, in September at the annual meeting of the European Society for Medical Oncology.
Regeneron Pharmaceuticals said the U.S. Food and Drug Administration has approved the use of Eylea for the treatment of diabetic macular edema.
BEIJING, July 28- Microsoft Corp appears to be the latest U.S. company targeted by China for anti-trust investigation after government officials paid sudden visits to the software firm's Chinese offices on Monday.
LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.
July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.
European shares closed higher on Thursday, after a business activity index showed the euro zone rebounded in July.
BASEL, July 24- Swiss drugmaker Roche confirmed its full-year sales and profit targets on Thursday as growing momentum for its new breast cancer medicines and professional diagnostics products countered the effects of a strong Swiss franc.
Roche confirmed its full-year outlook, but posted profit that missed expectations following an impairment charge at its diagnostics business.
Severin Schwan, CEO of Roche, says the company would consider a large acquisition if the "price is right" despite concerns over high valuations.